-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Hebei Guangxiang Receives Its First Patent Certificate
Category:
Time：2019-12-03
Recently, good news came from the National Intellectual Property Administration: the innovative technological achievement—“Continuous Cooling Crystallization Device for Theophylline Sodium Salt”—submitted by the Group Company and Hebei Guangxiang Pharmaceutical Co., Ltd. has been granted a utility model patent certificate. It is understood that this is the first patent certificate ever obtained by Hebei Guangxiang Pharmaceutical.
Recently, good news came from the National Intellectual Property Administration: the innovative technological achievement—“Continuous Cooling Crystallization Device for Theophylline Sodium Salt”—submitted by the Group Company and Hebei Guangxiang Pharmaceutical Co., Ltd. has been granted a utility model patent certificate. It is understood that this is the first patent certificate ever obtained by Hebei Guangxiang Pharmaceutical.
According to the R&D personnel, this project employs novel and advanced technologies to design a new type of practical device that significantly boosts the production efficiency of theophylline sodium salt. The device features a compact layout, reducing its footprint, and is capable of producing crystals with larger and more uniform particle sizes. The process control system operates on a DCS platform, enabling fully automated centralized control of process parameters, thereby ensuring process stability, enhancing the level of automation in production, and reducing labor intensity.
In recent years, the group has placed great emphasis on technological innovation, continuously attracting high-caliber talent, increasing investment in research and development, and placing strong focus on intellectual property protection. To date, the company has filed over 110 patent applications. These patented achievements have built up momentum for the company’s future development, enhanced the technological content of its products, and provided robust scientific and technological support for its sustained growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license